Bruce, Diana corp, I did not know Asencio was behind that one, if you count Solv-Ex then there are two that he short it till the end.
Weak,contradictory? sounds like Zona's patent, it is obvious
that a generic could not be turn into a new brand, unless new technology is add on (like a new delivery system, and still it is not
always a deterrent). Phentolamine Mesylate is the same IV form and the same old oral form. Is Zona waiting for the oral "method"? I was wrong before, I thought they did have it, but they are waiting (worst).
Asencio claimed that he contacted "investigators in the Zona trial" well he has the money to go around, I will not take that lightly. He shorts and does it with big money.
No contradiction in Asencio's words: He did not mentioned that "all" oral forms have drawbacks, he was talking about the Zorgniotti patent and this is clearly about phentolamine. Of course, he is trying to make his case with a praise of Viagra, self serving? that is exactly what he is there for.
Joe Podolski talk about future patent approval, is that disclosure? The only disclosure of interest is the full complete data out, and soon, other way this is going down because there is nothing to build on, the ongoin trial is future, FDA is far future, and Sales are years away.
Schering will only loose $10 millions (if at all) and this a good tax reporting shunk if it goes wrong. Many big pharmas have made mistakes investing in biotechs. And is already in the stock price.
Lawsuits? yes the Zona shareholders eventually will demand management, Asencio is not going to be stupid to put millions the way Shering does.
$5 dollars as target price, probably he is counting the company cash, other way it is going to $1.
I am not a short, and apparently there is already no more stock to short (does this mean that 50% of floating shares are shorted?) Then this is a case for a nice squeeze, if some strong statement (real full data disclosure) from the company comes out, then I will buy it. And that is my interest. |
